SEPN Septerna, Inc.

Nasdaq septerna.com


$ 23.78 $ 0.19 (0.81 %)    

Wednesday, 15-Oct-2025 12:26:06 EDT
QQQ $ 602.61 $ -1.19 (-0.2 %)
DIA $ 463.57 $ -1.06 (-0.23 %)
SPY $ 665.26 $ -1.52 (-0.23 %)
TLT $ 90.63 $ -0.33 (-0.36 %)
GLD $ 385.98 $ 0.04 (0.01 %)
$ 23.3
$ 23.31
$ 23.64 x 29
$ 23.82 x 100
$ 23.20 - $ 23.81
$ 4.17 - $ 28.99
363,708
na
1.03B
$ 2.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-20-2024 09-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Cantor Fitzgerald analyst Josh Schimmer reiterates Septerna (NASDAQ:SEPN) with a Overweight and maintains $25 price target.

Core News & Articles

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Septerna (NASDAQ:SEPN) with a Buy and maintains $26 price target.

Core News & Articles

Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) ...

Core News & Articles

Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.34) by...

 analyst-flags-septerna-as-undervalued-biotech-play-with-significant-upside

Septerna gains Buy rating as HC Wainwright highlights undervaluation, strong pipeline, and key partnership with Novo Nordisk in...

Core News & Articles

HC Wainwright & Co. analyst Raghuram Selvaraju initiates coverage on Septerna (NASDAQ:SEPN) with a Buy rating and announ...

Core News & Articles

Cantor Fitzgerald analyst Josh Schimmer maintains Septerna (NASDAQ:SEPN) with a Overweight and raises the price target from ...

Core News & Articles

Wells Fargo analyst Derek Archila maintains Septerna (NASDAQ:SEPN) with a Equal-Weight and raises the price target from $11 ...

 ozempic-maker-novo-nordisk-looks-for-new-chief-jrgensen-steps-down-from-ceo-role

Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains optimistic ...

Core News & Articles

Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.47) by...

 novo-nordisk-inks-22-billion-deal-with-septerna-to-develop-oral-weight-loss-and-diabetes-drugs

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and car...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION